Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084702981> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2084702981 endingPage "661" @default.
- W2084702981 startingPage "652" @default.
- W2084702981 abstract "Co-administration of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) with pioglitazone may improve glycemic control in patients with Type 2 diabetes due to their complementary mechanisms of action. This study aimed to investigate any potential pharmacokinetic interaction between linagliptin and pioglitazone, a CYP 2C8 substrate.20 (10 male and 10 female) healthy subjects, between 22 and 65 years of age with a BMI range of > = 18.5 and < =29.9 kg/m2, took part in this single center open-label, randomized,two-way cross-over study. The subjects were administered linagliptin 10 mg/day and/orpioglitazone 45 mg/day until steady state was reached.Co-administration of pioglitazone did not significantly affect linagliptin Cmax,ss (geometric mean ratio(GMR) 107.3; 90% confidence interval (CI);92.3 – 124.8) or AUC tau,ss (GMR 113.4; 90%CI 103.0 – 124.9). Co-administration of linagliptin did not significantly affect pioglitazoneAU tau,ss (GMR 94.4; 90% CI 87.1 –102.2), but reduced Cmax,ss by 14% (GMR85.6; 90% CI 78.1 – 93.8). As expected, linagliptin and pioglitazone were well tolerated,whether administered alone or concomitantly.There were no reported serious adverse events. The investigator defined 5 adverse events as drug-related with linagliptin,and 4 with pioglitazone.Linagliptinand pioglitazone have no clinically relevant pharmacokinetic interaction and may be co-administered without dose adjustment.These data further confirm that linagliptin is not an inhibitor of CYP2C8 in vivo.As the pharmacokinetic profiles of linagliptin and pioglitazone are similar in Type 2 diabetes patients and healthy subjects, it is reasonable to assume that they may be administered together to Type 2 diabetes patients without dose adjustment." @default.
- W2084702981 created "2016-06-24" @default.
- W2084702981 creator A5003565764 @default.
- W2084702981 creator A5021947247 @default.
- W2084702981 creator A5050453842 @default.
- W2084702981 creator A5056064349 @default.
- W2084702981 creator A5062930194 @default.
- W2084702981 date "2010-10-01" @default.
- W2084702981 modified "2023-09-26" @default.
- W2084702981 title "Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers" @default.
- W2084702981 doi "https://doi.org/10.5414/cpp48652" @default.
- W2084702981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20875371" @default.
- W2084702981 hasPublicationYear "2010" @default.
- W2084702981 type Work @default.
- W2084702981 sameAs 2084702981 @default.
- W2084702981 citedByCount "26" @default.
- W2084702981 countsByYear W20847029812012 @default.
- W2084702981 countsByYear W20847029812013 @default.
- W2084702981 countsByYear W20847029812014 @default.
- W2084702981 countsByYear W20847029812015 @default.
- W2084702981 countsByYear W20847029812016 @default.
- W2084702981 countsByYear W20847029812022 @default.
- W2084702981 crossrefType "journal-article" @default.
- W2084702981 hasAuthorship W2084702981A5003565764 @default.
- W2084702981 hasAuthorship W2084702981A5021947247 @default.
- W2084702981 hasAuthorship W2084702981A5050453842 @default.
- W2084702981 hasAuthorship W2084702981A5056064349 @default.
- W2084702981 hasAuthorship W2084702981A5062930194 @default.
- W2084702981 hasConcept C112705442 @default.
- W2084702981 hasConcept C126322002 @default.
- W2084702981 hasConcept C134018914 @default.
- W2084702981 hasConcept C197934379 @default.
- W2084702981 hasConcept C22979827 @default.
- W2084702981 hasConcept C2777180221 @default.
- W2084702981 hasConcept C2778384471 @default.
- W2084702981 hasConcept C2778763485 @default.
- W2084702981 hasConcept C2780031085 @default.
- W2084702981 hasConcept C555293320 @default.
- W2084702981 hasConcept C71924100 @default.
- W2084702981 hasConcept C97320921 @default.
- W2084702981 hasConcept C98274493 @default.
- W2084702981 hasConceptScore W2084702981C112705442 @default.
- W2084702981 hasConceptScore W2084702981C126322002 @default.
- W2084702981 hasConceptScore W2084702981C134018914 @default.
- W2084702981 hasConceptScore W2084702981C197934379 @default.
- W2084702981 hasConceptScore W2084702981C22979827 @default.
- W2084702981 hasConceptScore W2084702981C2777180221 @default.
- W2084702981 hasConceptScore W2084702981C2778384471 @default.
- W2084702981 hasConceptScore W2084702981C2778763485 @default.
- W2084702981 hasConceptScore W2084702981C2780031085 @default.
- W2084702981 hasConceptScore W2084702981C555293320 @default.
- W2084702981 hasConceptScore W2084702981C71924100 @default.
- W2084702981 hasConceptScore W2084702981C97320921 @default.
- W2084702981 hasConceptScore W2084702981C98274493 @default.
- W2084702981 hasIssue "10" @default.
- W2084702981 hasLocation W20847029811 @default.
- W2084702981 hasLocation W20847029812 @default.
- W2084702981 hasOpenAccess W2084702981 @default.
- W2084702981 hasPrimaryLocation W20847029811 @default.
- W2084702981 hasRelatedWork W2068691394 @default.
- W2084702981 hasRelatedWork W2084702981 @default.
- W2084702981 hasRelatedWork W2370929226 @default.
- W2084702981 hasRelatedWork W2766550598 @default.
- W2084702981 hasRelatedWork W2791450209 @default.
- W2084702981 hasRelatedWork W2797809097 @default.
- W2084702981 hasRelatedWork W2923907295 @default.
- W2084702981 hasRelatedWork W3018168093 @default.
- W2084702981 hasRelatedWork W4210689174 @default.
- W2084702981 hasRelatedWork W4225384168 @default.
- W2084702981 hasVolume "48" @default.
- W2084702981 isParatext "false" @default.
- W2084702981 isRetracted "false" @default.
- W2084702981 magId "2084702981" @default.
- W2084702981 workType "article" @default.